Jeil Pharma Holdings Inc

KRX:002620.KS

7980 (KRW) • At close December 26, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

20232022202120202019201820172016201520142013201220112010200920082007
Revenue 804,043.002792,964.733762,568.056761,996.752731,140.38142,736.34344,440.577617,279.88594,715.655512,736.239451,968.239426,819.209462,853.352431,307.03369,486.923319,439.855305,027.902
Cost of Revenue 589,458.611612,481.608582,061.262570,757.448549,162.61786,278.8523,133.368482,154.814454,500.267383,860.835342,551.577319,038.595329,679.984297,369.591248,373.494224,114.006208,135.013
Gross Profit 214,584.391180,483.126180,506.794191,239.304181,977.76256,457.49221,307.209135,125.066140,215.388128,875.404109,416.662107,780.614133,173.368133,937.439121,113.42995,325.84996,892.889
Gross Profit Ratio 0.2670.2280.2370.2510.2490.3960.4790.2190.2360.2510.2420.2530.2880.3110.3280.2980.318
Reseach & Development Expenses 46,037.53141,565.86139,673.22424,730.54422,451.5654,511.512700.86222,356.10420,298.62516,766.78718,085.87218,262.53517,591.48914,486.2488,354.8035,213.0375,316.565
General & Administrative Expenses 110,413.51143,210.49843,299.0533,620.95651,906.9975,731.2392,580.56318,082.05821,558.03220,838.92435,269.31331,850.32518,832.31916,105.24214,223.91213,822.02912,483.002
Selling & Marketing Expenses 37,213.16336,222.28543,029.25446,569.52438,258.96418,654.8687,564.77828,328.41228,560.65825,898.90210,369.92311,620.40421,060.30222,263.62927,173.31325,998.89126,784.438
SG&A 145,791.53979,432.78386,328.30480,190.4890,165.96124,386.10710,145.34146,410.4750,118.6946,737.82645,639.23643,470.72939,892.62138,368.87141,397.22539,820.9239,267.44
Other Expenses 067,032.44363,480.15463,837.08860,353.431,187.05335.7551,731.3841,606.8541,683.2781,413.1086,504.7861,027.795-379.102701.661813.169-1,130.367
Operating Expenses 193,664.205188,031.087189,481.682168,758.112172,970.95645,508.08521,015.059125,771.904127,066.954120,324.177108,043.895101,460.358101,671.06592,771.58282,572.40879,649.39679,101.222
Operating Income 20,920.186-7,547.9611,552.88534,682.39717,739.77610,949.407292.159,353.16113,148.4348,551.2271,372.7676,320.25632,819.82341,165.85738,541.02115,676.45317,791.667
Operating Income Ratio 0.026-0.010.0020.0460.0240.0770.0070.0150.0220.0170.0030.0150.0710.0950.1040.0490.058
Total Other Income Expenses Net -34,901.836-76,312.6662,845.68615,484.928-100,339.44-1,161.432746.011-3,511.3471,292.8533,283.083725.2287,307.764,490.6964,384.1475,431.78511,010.7777,326.381
Income Before Tax -13,981.65-83,860.626-6,129.20230,821.682-82,599.6649,787.9753,537.2613,802.38516,049.66211,834.312,097.99413,628.01637,310.51945,550.00443,972.80626,687.2325,118.048
Income Before Tax Ratio -0.017-0.106-0.0080.04-0.1130.0690.080.0220.0270.0230.0050.0320.0810.1060.1190.0840.082
Income Tax Expense -740.818-715.626,740.80415,880.62113,254.3472,486.346-489.515,912.136,288.2919,738.851,613.6082,456.17910,295.7320,079.80415,974.5569,152.40711,444.035
Net Income -16,249.744-83,145.006-12,870.00511,431.126-95,854.0117,069.964518,816.6227,890.2559,761.3712,095.459484.38611,171.83827,014.78825,470.227,998.2517,534.82313,674.013
Net Income Ratio -0.02-0.105-0.0170.015-0.1310.0511.6740.0130.0160.0040.0010.0260.0580.0590.0760.0550.045
EPS -1,059-5,416.22-838.38744.64-6,244.11,362.57139,1172,118.742,597.16550.19126.442,877.386,909.826,516.837,162.74,483.523,495.92
EPS Diluted -1,058.54-5,416.22-838.38744.64-6,244.11,362.57139,1172,118.742,597.16550.19126.442,877.386,909.826,516.837,162.74,483.523,495.92
EBITDA 33,476.297-72,711.6476,142.7143,333.144-78,887.05212,607.995,767.1156,132.88421,613.09119,597.76410,101.41819,463.138,798.01549,591.68347,625.66130,913.48730,237.42
EBITDA Ratio 0.042-0.0890.0140.0570.0350.0870.1640.0360.0420.0410.0270.050.0910.1150.1320.0970.099